Future Market Insights projects a 10.3% compound annual growth rate (CAGR) for the renal insufficiency treatment market from 2023 to 2033. The worldwide market for treatments for renal insufficiency is projected to reach a market worth of US$ 35.58 billion by 2033. The rising incidence of kidney illnesses, an aging population, and technical developments in the management of renal insufficiency are all factors contributing to the market’s expansion.

According to the Centres for Disease Control and Prevention (CDC), more than 37 Million people in the United States have kidney disease and over 700,000 Americans are living with kidney failure, also known as end-stage renal disease (ESRD). In addition, kidney disease is a leading cause of death worldwide, with over 1.2 Million deaths attributed to the disease in 2020 alone.

The increasing prevalence of kidney diseases is expected to drive the growth of the renal insufficiency treatment market, which includes a range of treatments for kidney failure and other renal disorders. These treatments include hemodialysis, peritoneal dialysis, kidney transplant, and medication.

Unlock Peak Performance - Get Your Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16898

Technological advancements in renal insufficiency treatment are also expected to drive the growth of the market. For example, the development of more advanced hemodialysis machines and catheters has made the procedure safer and more comfortable for patients, while the development of automated peritoneal dialysis machines has made peritoneal dialysis more accessible and convenient for patients.

Key Takeaways:

• The global renal insufficiency treatment market is expected to grow with a 10.3% CAGR from 2023 to 2033.
• By end user, dialysis centres are expected to hold 45% of the market share in 2023 for Renal insufficiency treatment market.
• North America is expected to possess 48% market share for Renal insufficiency treatment market in 2023.
• Europe Renal insufficiency treatment market size is expected to possess 41% market share in 2023.

“An increasing prevalence of kidney diseases, a growing aging population, and technological advancements in renal insufficiency treatment,” states an analysts at FMI

Competitive Landscape:

Key players in the renal insufficiency treatment are Nipro Corp., Fresenius Medical Care AG Co. KGaA, Baxter International, Inc., Medtronic Plc, Braun Melsungen AG, Asahi Kasei Medical Co., Ltd., Cantel Medical, Nikkiso Co., Ltd., JMS Co. Ltd., AstraZeneca

• Nipro Corporation produces a range of peritoneal dialysis products, including CAPD sets and cycler machines for automated peritoneal dialysis.
• Fresenius Medical Care produces a range of dialysis machines, dialyzers, bloodlines, and other equipment and supplies for use in hemodialysis and peritoneal dialysis treatment.

More Valuable Insights:

Future Market Insights, in its new offering, presents an unbiased analysis of the global Renal insufficiency treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Treatment Type (Dialysis, Medication, Kidney Transplantation) End User (Dialysis Centres, Hospital Clinics, Research Academic Institutes) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East Africa)

Key Segments:

By Treatment Type:

• Dialysis
• Medication
• Kidney Transplantation

By End User:

• Dialysis Centres
• Hospital Clinics
• Research Academic Institutes

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East Africa